Table 2.

Distribution of lesions

	Lesions included in the analysis	Histopathological confirmation
	(n = 597)	(n = 147)
Tumor type a,b
Lung cancer	104	40
Head and neck cancer	61	32
Gastrointestinal cancerc	129	24
Breast cancer	60	6
Lymphoma	125	20
Melanoma	26	10
Multiple melanoma	32	3
Otherd	60	12
Clinical question b
Diagnosis	22	10
Staging	20	11
Restaginge	33	18
Response to chemotherapy	58	6
Response to radiotherapy	18	6
Post-surgery evaluation	11	0
Surveillance	40	22
Site of disease b
Neck	93	33
Thorax	110	49
Abdomen	220	45
Skeleton-bone marrow	174	20
Lymph nodesf	198	32

Values are mean ± standard deviation.

^aTwo patients were not affected by any oncologic disease after histologic confirmation.

^bTumor type, clinical questions, and disease sites correspond to the groups submitted to the tumor-based and question-based analyses.

^cIncluding esophageal, gastric, and colorectal cancer.

^dGynecologic malignancy (n = 8) , testicular cancer (n = 2), sarcoma (n = 3), low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).

^eSuspected relapse or patients with potentially resectable metastatic disease.

^fLymph nodes were computed twice: according to their position in the body and independently from their position.